Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769412 · ClinicalTrials.gov registry record
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 550,000
- Enrollment target
NCT06769412 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 550,000 participants.
The verdict
NCT06769412 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 550,000 participants
- Enrollment target
Study Summary
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice. This study will also use clinical record review to confirm cases of RV first identified using International Classification of Diseases, tenth revision, Clinical Modification (ICD-10-CM) codes and to identify RV with occlusion.
Interventions
- DRUG aflibercept 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550,000 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2025-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06769412
The ClinicalTrials.gov registry entry for NCT06769412 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 550,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aflibercept 2 mg is the first listed.
NCT06769412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06769412 about?
NCT06769412 is a clinical study titled "A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)". This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice. This study will also use clinical record review to confirm cases of RV first identified using International Classifi...
What is the current status of trial NCT06769412?
This trial is currently completed. The enrollment target is 550,000 participants. The study started on 2025-07-01. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT06769412?
The interventions under investigation include: aflibercept 2 mg (DRUG).
Who is sponsoring clinical trial NCT06769412?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.